BactoReal® Kit *Haemophilus influenzae*

Kit version 1.1

Instructions for Use

CE

IVD **For *in vitro* diagnostic use**

REF **DHUB01053**

Σ **50 reactions**

ingenetix GmbH
Haidingergasse 1
1030 Vienna, Austria
T +43(0)1 36 198 01
office@ingenetix.com
www.ingenetix.com

Index

1. Intended purpose 3
2. Product description 3
3. Pathogen information 3
4. Principle of real-time PCR 4
5. Kit contents, stability and storage 4
6. Additionally required materials and devices 5
7. Precautions and safety information 5
7.1. General information 5
7.2. Specific information 5
8. Limitations 6
9. Preparation of samples 7
9.1. Sample collection and storage 7
9.2. Recommended extraction methods 7
9.3. Quality control for DNA extraction and PCR inhibition with IPC 7
9.3.1. Application of IPC as control of extraction and real-time PCR 7
9.3.2. Application of IPC as quality control for PCR reaction 8
10. Preparation of real-time PCR 8
10.1. Pipetting scheme 8
10.2. Programming of temperature profile 9
11. Interpretation of data 10
11.1. Controls 10
11.2. Clinical samples 11
12. Troubleshooting 11
12.1. No pathogen specific signal with positive control and with IPC 11
12.2. Pathogen signal with negative control 11
12.3. Pathogen signal with extraction negative control 11
12.4. IPC specific signal with negative control and positive control 12
12.5. No signal with IPC and no pathogen specific signal with sample 12
13. Specifications and performance evaluation 13
13.1. Kit performance 13
13.2. Limit of detection, LoD95% 14
13.3. Linearity and dynamic measuring range 14
13.4. Precision 14
12.5. Analytical specificity 14
12.6. Diagnostic evaluation 15
14. References 15
15. Revision history 15

Explanation of symbols

LOT	Batch code		Use by date
REF	Catalogue number		Manufacturer
Σ	Contains sufficient for <n> tests		Temperature limit (Store at)
CE	This product fulfils the requirements of the European Directive 98/79 EC for *in vitro* diagnostic medical devices	IVD	In vitro diagnostic medical device
	Consult instructions for use	UDI	Unique device identifier
	Keep away from sunlight	QTY	Contents

1. Intended purpose

BactoReal® Kit *Haemophilus influenzae* is a non-automated IVD real-time PCR test for the qualitative detection of DNA (omp P6 gene) of encapsulated and unencapsulated (also called nontypeable *H. influenzae*, NTHi) *H. influenzae* strains. The test also recognizes some strains of *Haemophilus haemolyticus* and *Haemophilus parainfluenzae*, albeit with less sensitivity.

Proper specimens are DNA extracts isolated from of samples of the respiratory tract and cerebrospinal fluid. This test is suitable for patients of all ages with suspected infection with *H. influenzae* and is intended as an aid in the diagnosis of infection with this pathogen in combination with patient history and additional clinical information.

The test is intended for professional use and is limited to qualified personnel instructed in the procedures of real-time PCR and *in vitro* diagnostic procedures.

2. Product description

BactoReal® Kit *Haemophilus influenzae* is a real-time PCR test and detects the outer membrane protein P6 (omp P6) gene of *Haemophilus influenzae.* This test detects both encapsulated and unencapsulated *H. influenzae* strains. The test also recognizes some strains of *Haemophilus haemolyticus* and *Haemophilus parainfluenzae*, albeit with less sensitivity.

A probe-specific amplification-curve in the FAM channel indicates amplification of *H. influenzae* specific DNA. The internal DNA positive control (IPC) is detected in the fluorescence channel Cy5 and serves as a control for DNA extraction and possible real-time PCR inhibition. The target for the DNA IPC (artificial target DNA) is added during sample extraction.

This test has been validated with the ABI® 7500 Fast Real-time PCR System (fast cycle parameters are not supported, Thermo Fisher Scientific) and tested with a LightCycler® 480 Instrument II (Roche Diagnostics) and Mx3005P® QPCR System (Agilent). It is also compatible with other real-time PCR instruments which detect and differentiate fluorescence in FAM and Cy5 channel (e.g., QuantStudio™ 5, QuantStudio™ 7 real-time PCR system (Thermo Fisher Scientific), qTOWER^{3}G (Analytik Jena), Mic instrument (bio molecular systems), cobas z 480 Analyzer (Roche)).

When using PCR-platforms not tested by ingenetix, an evaluation of the multiplex-PCR shall be done. Keep in mind that some PCR-platforms first must be calibrated with the corresponding dye before performing multiplex-PCR.

Ingenetix BactoReal®, ViroReal®, MycoReal®, PanReal and ParoReal® Kits are optimized to run under the same thermal cycling conditions. DNA and RNA can be analysed in one run.

3. Pathogen information

The 16 species of *Haemophilus* are Gram-negative bacteria occasionally colonizing the mucosa of humans and animals. Some *Haemophilus* species are the causative agents of various infections. For example, *H. aegyptius* causes purulent conjunctivitis, *H. parainfluenzae* is a rare cause of a form of endocarditis. *Haemophilus influenzae* can be found exclusively in the mucosa of humans, mainly in the upper respiratory tract. Transmission occurs through close contact with contaminated respiratory droplets. In sum, six capsular serotypes (a-f) can be distinguished, out of which type b (Hib) is the most prevalent and virulent one causing bloodstream infections and meningitis mainly in children less than 5 years. In contrast, unencapsulated strains (also called nontypeable *H. influenzae*, NTHi) of *H. influenzae* are part of the normal bacterial flora of humans and are occasionally pathogen. These strains can cause otitis, sinusitis, epiglottitis, bronchitis, pneumonia and less frequently meningitis and bacteraemia. The Omp P6 gene of *H. influenzae* is present in both the encapsulated and unencapsulated strains of *H. influenzae.*

4. Principle of real-time PCR

The test is based on multiplex real-time PCR by 5´-nuclease-assay technology. Specific DNA sequences are amplified and the generated PCR-products are detected by oligonucleotide-probes labelled with fluorescent dyes. This allows a sequence-specific detection of PCR amplificates.

During PCR, primers are extended by *Taq* polymerase and probes hybridized to the target are cleaved by the 5'-exonuclease activity of *Taq* polymerase. According to the accumulation of PCR product, the fluorescence of the probe increases with each PCR cycle. The change in fluorescence of the different dyes is recorded cycle by cycle in the real-time PCR instrument in the closed reaction tube at different fluorescence wavelengths.
The Cq value (Cq = Quantification cycle, Ct = Cycle threshold, Cp = Crossing point) describes the cycle at which the fluorescence first rises significantly above the background fluorescence.

5. Kit contents, stability and storage

Table 1

Labelling	**Content**	**Amount**	**Storage**
Haemophilus influenzae + IPC3 Assay Mix (green cap)	Primers and probes for detection of - *H. influenzae* (FAM) - DNA IPC (Cy5)	1 x 50 µl	-25 to -15 °C
IPC-Target (DNA) (orange cap)	Target for DNA IPC (internal DNA positive control system)	1 x 200 µl	-25 to -15 °C
Haemophilus influenzae Positive Control (red cap)	DNA positive control (approx. 1,000 target copies/µl)	1 x 300 µl	-25 to -15 °C
DNA Reaction Mix (white cap)	PCR reaction mix for DNA amplification	1 x 500 µl	**-25 to -15°C after first opening 2 to 8 °C**
Nuclease-free water (blue cap)	Nuclease-free water	1 x 1000 µl	-25 to -15 °C

DNA Reaction Mix
The Master Mix provided with the kit has been designed for reliable, high-sensitivity real-time PCR. The Master Mix contains a highly purified Taq Polymerase for rapid hot-start PCR, dNTPs with dUTP and Uracil-N glycosylase (UNG) to eliminate amplicon carryover, ROX™ dye (passive reference) and buffer components – additives optimized to handle RT-PCR inhibitors.

Delivery and Storage
Shipment is with dry ice or with coolpacks. When stored properly, the kit components are stable until the specified expiration date. This also applies after opening. Store kit protected from light.

Quality Control Release Testing
In accordance with the ISO 13485 certified Quality Management System of ingenetix, each lot is tested against predetermined specifications to ensure consistent product quality. Quality control is performed with a plasmid containing parts of the pathogen DNA.

6. Additionally required materials and devices

- Reagents and devices for DNA-extraction which are appropriate for the listed sample material (see 9. Preparation of the samples)
- Nuclease-free water
- Powder-free disposable gloves
- Pipettes (adjustable)
- Filter pipette tips
- Vortex-Mixer
- Benchtop centrifuge with rotor for 2 ml reaction tubes
- Real-time PCR instrument detecting and differentiating fluorescence in FAM and Cy5 channel (see 2. Product description)
- Appropriate 96 well optical reaction plates or reaction tubes with corresponding (optical) closing material
- Optional: Laminar flow box
- Optional: PCR workstation

7. Precautions and safety information

7.1. General information

- For *in vitro* diagnostic use. The use of this kit is limited to qualified personnel instructed in real-time PCR and *in vitro* diagnostic procedures.
- Transportation of clinical specimens must comply with local regulations for the transport of biological materials.
- Specimens should be handled as if infectious in accordance with safe laboratory procedures. Wear protective powder-free disposable gloves when handling kit reagents and specimens.
- Discard specimens, reagents, and waste according to your local safety regulations.
- Improper collection, transport or storage of specimens may hinder the ability of the assay to detect the target sequences.
- Quality of DNA has a profound impact on the test performance. Ensure that the used DNA extraction system is compatible with real-time PCR technology.
- Protect kit components from light.
- The real-time PCR instrument should be calibrated, serviced and cleaned regularly.
- Avoid mixing reagents of different kits and lots and check expiry date of the kit.

7.2. Specific information

A workflow must be followed to avoid false positive results due to detection of contaminating DNA.

<u>Recommended measures to avoid DNA contamination:</u>

- Use separated workspaces for specimen preparation, set-up of real-time PCR and amplification. Supplies and equipment must be dedicated to each of these separate workspaces to ensure workflow in the laboratory from pre- to post-PCR.
- Laboratory benches and devices must be cleaned regularly.
- Sample preparation should be performed in a laminar flow box. Clean laminar flow box regularly in all areas.
- If possible, leave consumables and pipettes in the laminar flow sterile bench and PCR workstation.
- Preparation of real-time PCR should be done in a PCR workstation.
- The use of sterile aerosol-resistant pipette tips is required.
- Use only DNA-free consumables.
- Wear lab coat.
- Work only with powder-free disposable gloves, do not touch the outer surface of the palm and fingers of the gloves when putting them on. Change gloves frequently. To avoid skin contact, wear gloves over the sleeves of the lab coat. Use disposable sleeve protectors if possible.
- Do not touch the rim or threads of open vials.
- Caution is advised when handling specimens and positive control to avoid cross-contamination.
- Store positive and potentially positive material separately from all other reagents.
- For a valid interpretation of results, a negative control shall be included during DNA-extraction (e.g., extraction of water instead of sample material), in to exclude false-positive results due to contamination with DNA of pathogen during extraction.
- Optional: include a negative control of PCR per PCR-run (nuclease-free water instead of sample, NTC).

8. Limitations

- Reliable results with this test are only achieved by appropriate specimen collection, transport, and storage, as well as an appropriate DNA extraction procedure.
- Detection of *H. influenzae* has been confirmed with cerebrospinal fluid extracts, and DNA isolation and detection of *H. influenzae* has been validated with sputum samples with this kit. Test performance with other specimen types has not yet been assessed.
- A negative test result does not exclude the possibility of *H. influenzae* infection, because test results may be affected by improper specimen collection, technical error, specimen mix-up or pathogen quantities below the assay sensitivity. PCR inhibitors may lead to invalid results.
- For this kit highly specific primers and probes have been selected. However, false-negative, or less sensitive results might be obtained due to sequence heterogeneity within the target region of not yet described clinical subtypes.
- Results should be interpreted in context of other clinical and laboratory findings since *H. influenzae* can also colonize the mucous membrane of healthy persons in low concentrations.

9. Preparation of samples

BactoReal® Kit *Haemophilus influenzae* is suitable for analysis of DNA extracts from samples from the human respiratory tract and cerebrospinal fluid.

Sample preparation should be performed with the recommended measures to avoid DNA contamination (see precautions and safety information). Always include a DNA extraction negative control (e.g., extraction of water).

Purified DNA should be stored at -25 to -15 °C.

9.1. Sample collection and storage

Samples from the respiratory tract and CSF can be stored in microcentrifuge tubes.
Swabs can be collected with swab material proper for PCR (e.g., sterile polyester or rayon swabs with aluminium or plastic shaft) and put into 1 ml isotonic saline solution (NaCl 0.9%, not provided).

It is recommended to process samples immediately after collection. Store samples at 2-8 °C for no longer than 48 hours or freeze at -20/-80 °C.

9.2. Recommended extraction methods

Ensure that the extraction system used is not contaminated with DNA of pathogens detected with BactoReal® Kit *Haemophilus influenzae.* Extract the sample using a DNA extraction system compatible with real-time PCR technology and appropriate for the sample material.

For manual extraction recommended
- QIAamp DNA Mini Kit (Qiagen)

For automated extraction recommended
- innuPREP AniPath DNA RNA – KFFLX Kit (Analytik Jena) with the KingFisher FLEX instrument (Thermo Fisher Scientific)

When using extraction methods not recommended by ingenetix, an evaluation of the extraction method must be performed.

9.3. Quality control for DNA extraction and PCR inhibition with IPC

The DNA IPC system (internal DNA positive control) is used as a control for DNA extraction, identifies possible PCR inhibition and confirms the integrity of kit reagents.
For this, an artificial target DNA (IPC-Target (DNA), approx. $6x10^5$ copies/µl) is added during extraction.

Note: The Cq values of the IPC depend on the extraction method and on the type of sample material. Negative samples should show Cq values of the IPC between 27-30. The extraction method used must be validated accordingly with sample material. Use the IPC-Target (DNA) freshly diluted (1:10 with nuclease-free water) in the extraction, if Cq values < 27 are determined during validation with samples.

9.3.1. Application of IPC as control of extraction and real-time PCR

The IPC-Target (DNA) must be added during extraction.

→ Per sample spike 1 µl IPC-Target (DNA) (orange cap) directly into the appropriate volume of lysis buffer (or spike it to the sample after the lysis buffer has been added to the sample), then continue the extraction procedure.

Caution: The IPC-Target (DNA) shall not be added to sample material in the absence of lysis buffer, as degradation may occur. It must be added to the lysis buffer.

9.3.2. Application of IPC as quality control for PCR reaction

If the IPC-Target (DNA) has not been added during extraction, it can be added at a later stage to the PCR master mix.

→ Freshly dilute the IPC-Target (DNA) 1:100 with nuclease-free water and add 1 µl of the dilution/PCR reaction (approx. 6000 target copies).

Caution: The IPC-Target (DNA) shall not be added to the master mix undiluted.

10. Preparation of real-time PCR

- Include one positive control (red cap), one extraction negative control and optionally one PCR negative control (NTC, e.g., nuclease-free water) per PCR run.
- It is generally recommended to analyse samples in duplicates, which increases the probability of pathogen detection and facilitates interpretation of results.
- Thaw DNA samples on ice.
- Thaw kit components completely at room temperature. When thawed, mix components carefully, centrifuge briefly with low speed.
- Mix the DNA Reaction Mix gently to ensure homogeneity of solution.
- **Positive Control**
  → Use 9 µl of Positive Control (red cap). Always, pipette positive control at last.

10.1. Pipetting scheme

		Per sample
Preparation of Master Mix (mix well)	DNA Reaction Mix	10.0 µl
	Haemophilus influenzae + IPC3 Assay Mix	1.0 µl
	Total volume Master Mix	**11.0 µl**
Preparation of PCR	Master Mix	11.0 µl
	DNA-sample*	9.0 µl
	Total volume	**20.0 µl**

*1-9 µl of the sample can be used. For ≠ 9 µl sample, the volume must be adjusted with nuclease-free water.

→ **If IPC-Target (DNA) was not added during extraction:** Freshly dilute the IPC-Target (DNA) (orange cap) 1:100 with nuclease-free water and add 1 µl per sample directly to the master mix. In this case, the IPC is used for quality control of the PCR reaction. Only 8 µl of DNA sample can be analyzed.
Caution: The use of more than 1 µl diluted IPC-Target (DNA) per reaction might cause inhibition of the real-time PCR reaction.

- Prepare the Master Mix according to the number of samples, calculating an additional volume of approx. 10% for pipetting loss.
- Pipette 11 µl of the prepared Master Mix per sample into the well of the optical reaction plate.
- Then add 9 µl of the extracted sample or controls. Pipette the positive control at last.
- Seal the plate with a suitable optical sealing material.
- Vortex the sealed plate for 1-2 seconds and briefly centrifuge the plate.

10.2. Programming of temperature profile

Please find further information on programming of the real-time PCR instrument in the respective operator's manual. Keep in mind that some PCR-platforms must be calibrated with the corresponding dye before performing a multiplex-PCR.

Sample Volume: 20 µl
Ramp speed: "Standard" without "fast cycling" parameter for ABI® 7500 Fast Instrument, QuantStudio™ (Thermo Fisher Scientific)

Program 1 Cycles: 1 Analysis: None	**Program 2** Cycles: 1 Analysis: None	**Program 3** Cycles: 45 Analysis: Quantification Acquisition at 60 °C
50 °C 2 min	95 °C 2 min	95 °C 5 sec 60 °C 1 min

Ad program 1: If viral RNA should be also detected in the same PCR run, program 1 must be prolonged to 15 min at 50 °C. This temperature profile can be used for all ingenetix ViroReal®, BactoReal®, MycoReal®, PanReal and ParoReal® kits for the detection of DNA or RNA.
Ad program 2: the previous temperature profile with 20 sec in program 2 can still be used.

<u>Select detection channels</u>

FAM channel: Detection of *Haemophilus influenzae*
Cy5 channel: Detection of IPC

For ABI® 7500 Instrument, QuantStudio™ 5/6/7 (Thermo Fisher Scientific), Mx3005P® (Agilent)
FAM-TAMRA
Cy5-NONE
Passive refence dye: ROX

For MIC Instrument (bio molecular systems)
FAM Green
Cy5 Red
Passive reference dye: no ROX needed

For cobas z 480 Analyzer / LightCycler® 480 II (Roche)
Detection format: 2 Color Hydrolysis Probe
FAM: Excitation at 465 nm, Emission at 510 nm
Cy5: Excitation at 610 / 618 nm, Emission at 670 / 660 nm
Passive reference dye: no ROX needed

11. Interpretation of data

For the analysis of the PCR results, select the fluorescence display options FAM channel for the pathogen target and Cy5 channel for the IPC.
Please note that some PCR platforms require Color Compensation when using a multiplex PCR.

IMPORTANT: Samples should be checked in both logarithmic (Roche instrument: Abs Quant/Fit Points) and linear view and compared to the negative controls. In addition to the Cq values, also check the amplification curves and adjust the threshold (noise band) if necessary.
After you have saved the new settings, export the data. For the cobas z 480 Analyzer, export tables per dye.

Assessment of clinical specimen test results should be performed after the positive and negative controls have been examined and determined to be valid. If results of controls are not valid, no interpretation of results with clinical samples is possible.

Negative samples:
Samples without amplification curves (no Cq values, undetermined) are regarded as negative. No DNA was detected in these samples because there is no infection with the corresponding pathogen or the pathogen DNA concentration is below the detection limit of the test.

Positive samples:
Samples with Cq values < 45 in the fluorescence channel for the pathogen target are regarded as positive.

Table 2 shows the criteria for valid positive and negative controls. Table 3 shows interpretation of data with clinical samples.

11.1. Controls

Table 2: Criteria for valid controls, IPC-Target (DNA) was added during extraction

	Cq FAM channel *H. influenzae* target	Cq Cy5 channel IPC[1]	Interpretation	Action
Positive control	< 29	Negative	Valid	-
Positive control	Negative	Negative	Invalid	See 12.1
Extraction negative control	Negative	27-30[2]	Valid	-
Extraction negative control	Negative	Negative	Invalid	See 12.1
Extraction negative control	Positive	27-30[2]	Invalid	See 12.3
NTC PCR (optional)	Negative	Negative	Valid	-
NTC PCR (optional)	Positive	Negative	Invalid	See 12.2

[1] If the IPC-Target (DNA) was added directly to the master mix, all samples in the Cy5 channel must be positive.
[2] Cq values of the IPC are dependent on the extraction method and should show Cq values of 27-30 (see 9. preparation of samples).

11.2. Clinical samples

Samples with positive Cq-values are interpreted as positive, see **Fehler! Verweisquelle konnte nicht gefunden werden.**.

Table 3 Interpretation of data with clinical samples

	Cq FAM channel *H. influenzae* target	Cq Cy5 channel IPC	Interpretation	Action
Clinical sample	Negative	27-30[1]	Negative	-
Clinical sample	Positive	Positive/Negative[2]	Positive	-
Clinical sample	Negative	Negative	Invalid	See 12.5

[1] A positive signal of the IPC excludes potential PCR inhibition. However, IPC Cq-values should show comparable results among samples. A shift of Cq- values can indicate a partial inhibition of PCR. Cq values of the IPC are dependent on the extraction method and should show Cq values of 27-30 (see 9. preparation of samples).
[2] High pathogen loads in the sample can lead to a reduced or absent fluorescence signal of the IPC.

In case of invalid data, analysis must be repeated with the remaining or newly extracted DNA sample (see 12. Troubleshooting).

12. Troubleshooting

12.1. No pathogen specific signal with positive control and with IPC

- Incorrect programming of the temperature profile or incorrect setting of detection channels on the real-time PCR instrument.
  → Compare temperature profile and setting of detection channels with details specified in the protocol
- Incorrect configuration of PCR reaction.
  → Check your pipetting steps with the pipetting scheme and repeat PCR, if necessary.
  → The DNA may have been degraded.
- The IPC-Target (DNA) was added undiluted directly to the master mix and not freshly diluted 1:100. The PCR reaction is therefore inhibited.
  → Freshly dilute IPC-Target (DNA) 1:100 and repeat PCR.
- No Positive Control was added.
  → Repeat PCR in case all clinical samples are negative.
- For control of real-time PCR only: 1 µl of freshly 1:100 diluted IPC-Target (DNA) must be added to the master mix. If the addition of IPC-Target has been forgotten:
  → Freshly dilute IPC-Target (DNA) and repeat PCR.
- For control of DNA extraction and PCR inhibition, the undiluted IPC-Target (DNA) must be added during extraction to the lysis buffer. If the IPC-Target (DNA) was missed to be added:
  → Repeat DNA extraction.

12.2. Pathogen signal with negative control

- If there are Cq values in the negative control below the cut-off specified in the Instructions for Use, a contamination occurred during the preparation of the PCR.
  → Repeat PCR with new reagents in replicates.
  → Strictly pipette positive control at last.
  → Make sure that workspace and instruments are cleaned at regular intervals.

12.3. Pathogen signal with extraction negative control

- If there are Cq values in the negative control of extraction below the cut-off specified in the Instructions for Use, a contamination occurred during the preparation of the PCR or the DNA extraction.
  → Repeat the PCR with unused reagents in replicates.
  → If repeatedly positive: Repeat DNA extraction and PCR using new reagents.
  → Strictly pipette positive control at last.

→ Make sure that workspace and instruments are cleaned at regular intervals and that workstations are separated from samples with high pathogen concentration.

12.4. IPC specific signal with negative control and positive control

- The IPC-Target (DNA) has been added to lysis buffer during extraction, but there is IPC specific signal with negative control and positive control: Contamination with the IPC-Target (DNA).
  → Make sure that workspace and instruments are cleaned at regular intervals.

12.5. No signal with IPC and no pathogen specific signal with sample

- Incorrect assignment of detection channels in sample.
  → Please verify the correct assignment of detection channels.
- The DNA might be degraded.
- If the IPC-Target (DNA) was added during extraction:
  - Inhibition of PCR may have occurred.
  - DNA extraction was unsuccessful.
  - The IPC-Target (DNA) was not added to the lysis buffer of the sample.
  - The extracted sample was not added to the PCR-reaction.

  → No statement is possible. Verify you use a recommended method for DNA isolation and re-examine the single steps of the DNA extraction.

  → If no operating mistakes during DNA extractions can be retraced, it is recommended to repeat the PCR with lower amounts of DNA-eluate (1/5 or 1/10 of sample volume + the adequate volume of nuclease-free water).

13. Specifications and performance evaluation

13.1. Kit performance

Performance of BactoReal® Kit *Haemophilus influenzae* with an ABI® 7500 instrument (Thermo Fisher Scientific) is shown in Figure 1.

Logarithmic view	Linear view
	
ABI® 7500: FAM channel 1:10 serial dilution of a *Haemophilus influenzae* DNA target	
	
ABI® 7500: FAM channel *Haemophilus influenzae* positive control	
	
ABI® 7500: Cy5 channel Internal DNA positive control	

Figure 1 Performance of BactoReal® Kit *Haemophilus influenzae*

This test has been validated with the ABI® 7500 instrument (Thermo Fisher Scientific) and was also tested with a LightCycler® 480 II (Roche Diagnostics) and Mx3005P® (Agilent).

13.2. Limit of detection, LoD95%

Method: BactoReal® Kit *Haemophilus influenzae* was tested with a 10-fold dilution series of a plasmid containing a fragment of *Haemophilus influenzae* DNA. The limit of detection (LoD95%: number of target copies detected in 95% of cases) was determined with plasmid dilutions around the analytical sensitivity using a non-linear curve fitting with the Graph Pad Prism Software.

Result: At least 10 target copies/reaction could be detected. The LOD95% is 36 target copies/reaction.

13.3. Linearity and dynamic measuring range

Method: Linearity was determined using a 10-fold serial dilution (10^6 – 10^1 target copies/reaction) of the plasmid. The number of determinations (n) per dilution was nine.

Result: The assay shows linearity over the range of 100 to 1,000,000 target copies/reaction with a slope of -3.34 ± 0.02 and an R^2 of > 0.99 as shown in Figure 2.



Figure 2 Ten-fold dilution series of a *Haemophilus influenzae* DNA standard plotted against CT

13.4. Precision

Method: Precision within a run (intra-assay), between multiple runs (inter-assay) and between two lots (inter-lot) was determined.

Result: The mean values of the coefficients of variation (CV%) are 0.6% for intra-assay precision, 0.5% for inter-assay precision and 1.0 for inter-lot precision.

12.5. Analytical specificity

Method BLAST analysis: The selection of highly specific primers and probes ensures analytical specificity. *In silico* validation of primers and probes was carried out with the basic local alignment search tool (BLAST) against the NCBI database. Primers and probes have been checked for possible homologies to currently published sequences by sequence comparison analysis. This approach validates the detection of so far known *Haemophilus influenzae* strains.

Result: No relevant sequence variability was observed in the primer and probe region of *Haemophilus influenzae* strains. This analysis revealed a possible cross-reaction with some strains of *H. haemolyticus* and *H. parainfluenzae*, albeit with lower sensitivity.

Method testing inclusivity: 50 isolates of *Haemophilus influenzae* from cultures of clinical specimens and one isolate of *Haemophilus influenzae* b were tested.

Result: All 51 isolates were positive with BactoReal® Kit *Haemophilus influenzae*.

Method testing exclusivity: Genomic DNA of Adenovirus, *Haemophilus aphrophilus, Haemphilus parainfluenzae, Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Streptoccocus pneumoniae* was tested.

Result: No cross-reactions were observed.

12.6. Diagnostic evaluation

Method: DNA extracts from 38 sputum samples were tested with BactoReal® Kit *Haemophilus influenza*. In addition, these samples were tested with a real-time PCR assay from another manufacturer (Primerdesign/Genesig, order no. JN1 48333-45668) and a conventional PCR reference method.
Furthermore, DNA from extracted CSF was mixed with *H. influenzae* DNA and tested.

Result: All samples that were positive with BactoReal® Kit *Haemophilus influenza* also showed a positive signal with both reference methods. Sequencing showed in some cases the presence of *H. haemolyticus* and *H. parainfluenzae*, which were also amplified by the reference methods. However, superimposition of *H. influenzae* by these bacteria cannot be excluded. By conventional PCR and sequencing, it was shown that the mostly weakly positive samples (Cq > 30) corresponded to *Haemophilus haemolyticus* and *Haemophilus parainfluenzae*, whereas the mostly strongly positive samples (Cq < 30) were confirmed as *Haemophilus influenzae*.
Samples negative with BactoReal® Kit *Haemophilus influenza* were also sequenced. These samples were identified as *H. parainfluenzae* and *H. haemolyticus*. This is an indication that not all *H. parainfluenzae* and *H. haemolyticus* strains cross-react with BactoReal® Kit *Haemophilus influenza*.
All CSF samples were analyzed correctly.

14. References

Kunze W, Müller L, Kilian M, Schuhmann MU, Baumann L, Handrick W. 2008. Recurrent posttraumatic meningitis due to nontypable Haemophilus influenzae: case report and review of the literature. Infection. 36:74-77.

15. Revision history

Revision	Date	Description
1.3en	01 May 2023	**Change of the company address** **Explanation of symbols** Update **1. Intended purpose** Intended use specified in more detail **5. Contents, stability and storage** Kit version 1.1: Filling volume of IPC-Target (DNA) and Positive Control was changed. The DNA IPC Target is not stored in RNA/DNA Stabilizer anymore and was renamed to IPC-Target (DNA). IPC-3 Assay Mix has been removed. The former DNA IPC-3 Assay Mix is now included in the Haemophilus influenzae Assay Mix. **5. Additionally required materials and equipment** Update **6. Precautions and safety instructions** Addition of additional information on specimen collection and storage, processing of specimens after collection, storage conditions of specimens, transport and storage conditions of purified DNA. **7. Precautions and safety instructions** Update of this section

Revision	Date	Description
		Inclusion of additional information on specimen collection and storage, processing of specimens after collection, storage conditions of specimens, transport and storage conditions of purified DNA. Recommended measures to avoid DNA contamination added. **9. Preparation of samples** innuPREP AniPath DNA RNA - KFFLX Kit added Note that for Cq values < 27, the IPC-Target (DNA) must be diluted prior to extraction. **10. Preparation of real-time PCR** The pipetting scheme has changed. The temperature profile has changed - the activation step in program 2 has been extended from 20 sec to 2 min. **11. Interpretation of PCR data** Definition of Cq, Ct and Cp values. Update tables for results with positive and negative controls and clinical samples. Inclusion of an explanation of how to evaluate clinical specimen test results in relation to controls. **12. Troubleshooting** Update regarding references in the new results tables. **13. Specifications and performance evaluation** Update.

Note:
Any serious incident that has occurred in relation to the product shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Technical support
ingenetix GmbH, Haidingergasse 1, 1030 Vienna, Austria
Telephone: +43 (0)1 36 198 01; **E-Mail:** office@ingenetix.com